UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000027304
Receipt No. R000031263
Scientific Title A study on the effect of diabetes drugs (SGLT2 inhibitor and DPP4 inhibitor) for nonalcoholic fatty liver disease
Date of disclosure of the study information 2017/05/15
Last modified on 2020/11/13 (Ver. 5)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title A study on the effect of diabetes drugs (SGLT2 inhibitor and DPP4 inhibitor) for nonalcoholic fatty liver disease
Acronym A study on the effect of diabetes drugs (SGLT2 inhibitor and DPP4 inhibitor) for nonalcoholic fatty liver disease
Scientific Title A study on the effect of diabetes drugs (SGLT2 inhibitor and DPP4 inhibitor) for nonalcoholic fatty liver disease
Scientific Title:Acronym A study on the effect of diabetes drugs (SGLT2 inhibitor and DPP4 inhibitor) for nonalcoholic fatty liver disease
Region
Japan

Condition
Condition nonalcoholic fatty liver disease
Classification by specialty
Hepato-biliary-pancreatic medicine
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To examine the effect of diabetes treatment drugs on nonalcoholic fatty liver disease.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes The rate of change of ALT value after 12 weeks from the start of administration
Key secondary outcomes

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Randomized
Randomization unit Cluster
Blinding Double blind -all involved are blinded
Control Active
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 For 12 weeks, dapagliflozin 5 mg is administered daily.
Interventions/Control_2 For 12 weeks, tengliptin 5 mg is administered daily.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
80 years-old >
Gender Male and Female
Key inclusion criteria Nonalcoholic fatty liver disease case without diabetes mellitus
Key exclusion criteria Cases with severe heart, liver and kidney disease
Target sample size 20

Research contact person
Name of lead principal investigator
1st name Tobita
Middle name
Last name Hiroshi
Organization Shimane University Hospital
Division name Department of Hepatology
Zip code 693-8501
Address 89-1 Enya-cho, Izumo, Shimane
TEL 0853202190
Email ht1020@med.shimane-u.ac.jp

Public contact
Name of contact person
1st name Tobita
Middle name
Last name Hiroshi
Organization Shimane University Hospital
Division name Department of Hepatology
Zip code 693-8501
Address 89-1 Enya-cho, Izumo, Shimane
TEL 0853-20-2190
Homepage URL
Email ht1020@med.shimane-u.ac.jp

Sponsor
Institute Department of Hepatology, Shimane University Hospital
Institute
Department

Funding Source
Organization Department of Hepatology, Shimane University Hospital
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Shimane University School of Medicine Medical Ethics Committee
Address 89-1 Enyacho, Izumo City, Shimane Prefecture
Tel 0853-20-2515
Email kenkyu@med.shimane-u.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 島根大学医学部附属病院

Other administrative information
Date of disclosure of the study information
2017 Year 05 Month 15 Day

Related information
URL releasing protocol private
Publication of results Unpublished

Result
URL related to results and publications in press
Number of participants that the trial has enrolled 26
Results
Administration of SGLT2 inhibitors or DPP4 inhibitors significantly reduced ALT levels.
Results date posted
2020 Year 11 Month 13 Day
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Nonalcoholic fatty liver disease (NAFLD) patients without type 2 diabetes mellitus (T2DM)
Participant flow
NAFLD patients without T2DM were enrolled in this single center double-blind randomized prospective study, and allocated to receive either SGLT2 inhibitor or DPP4 inhibitor for 12 weeks.
Adverse events
no special instruction
Outcome measures
HbA1c, ALT, body composition, etc.
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2017 Year 05 Month 11 Day
Date of IRB
2017 Year 04 Month 24 Day
Anticipated trial start date
2017 Year 05 Month 15 Day
Last follow-up date
2018 Year 04 Month 06 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2017 Year 05 Month 11 Day
Last modified on
2020 Year 11 Month 13 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000031263